Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This preliminary study observed that topical nitrogen mustard was beneficial for only 1 out of 6 patients with extensive alopecia areata, with 4 patients not completing the trial.

This study validated the differential stripping technique on hairless rat skin and found that the P-08–016 formulation delivered more finasteride to the epidermis and appendages compared to P-10–008.

This study found that alopecia areata patients who responded poorly to topical immunotherapy had impaired peripheral blood mononuclear cell responses to T-cell stimulants.

This study found that higher concentrations of topical diphenylcyclopropenone, especially when prepared with acetone, showed better stability over 6 months compared to lower concentrations.

This study found that diphenylcyclopropenone (DPCP) was more effective and better tolerated than dinitrochlorobenzene (DNCB) in promoting hair regrowth in patients with alopecia areata.

In this study, topical tacrolimus 0.03% cream showed good to excellent response in treating alopecia areata in 70% of participants, with no cutaneous or systemic side effects observed.

In this study, tapering prednisone followed by 2% topical minoxidil helped limit hair loss in some patients with alopecia areata, with 30% to 47% showing over 25% hair regrowth initially.

In this study, topical tofacitinib significantly increased hair regrowth in mice compared to minoxidil or vehicle, potentially due to elevated VEGF levels and reduced inflammation.

This study found that maintenance treatment with diphenylcyclopropenone was associated with a lower relapse rate in alopecia areata patients, highlighting the importance of adjusting treatment intervals post-improvement.

Avoiding dyed wigs and clothing improved severe allergic reactions in a woman treated with diphencyprone.

In this study, alopecia areata patients treated with diphencyprone showed a significant increase in CD8 lymphocytes around hair bulbs, which may be associated with hair regrowth.

This study reviewed existing articles to assess the efficacy of topical diphenylcyclopropenone immunotherapy for alopecia areata, but it did not report new clinical results.

In this study, anthralin treatment led to hair regrowth in alopecia areata-like affected C3H/HeJ mice, suggesting it may be an effective therapy for this condition.

This case report describes a 30-year-old Brazilian male who developed vitiligo lesions following diphencyprone therapy for alopecia areata.

This review discusses current and emerging drug therapies for treating androgenetic alopecia and alopecia areata, and reports no clinical results; it highlights a need for improved and novel treatments.

This review discusses the efficacy and safety of topical sensitizers for treating alopecia areata and reports no new clinical results; it emphasizes advancements in pediatric use, molecular mechanisms, and targeted delivery methods.

This review discusses various treatment options for alopecia areata, noting a lack of consensus on grading and treatment algorithms, and reports no new clinical results.

Most children with alopecia areata improved with treatment, but those with more hair loss had worse outcomes.

This study found that topical Dithranol 0.5% is more effective than topical Tacrolimus 0.1% for hair regrowth in patients with alopecia areata, with 40% of Dithranol-treated patients showing over 80% hair regrowth compared to 23.33% for Tacrolimus-treated patients.

This study found that both Betasalic ointment and 5% minoxidil resulted in acceptable hair regrowth for patients with alopecia areata over a three-month period, with any adverse effects being transient.

This review discusses the advancements in understanding and treating androgenetic alopecia and alopecia areata but reports no clinical findings; the authors emphasize the need for further research on molecular control mechanisms.

This study observed that topical PUVA treatment led to excellent or good hair regrowth in 45.4% of patients with alopecia areata, though many experienced relapse after treatment stopped.

This review discusses various treatment options for alopecia areata tailored by age and severity, providing a practical algorithm, but reports no new clinical results.

This review examined the role, efficacy, and safety of Janus kinase inhibitors in treating alopecia areata, noting that baricitinib has received approval as the first on-label treatment due to positive outcomes in multiple trials.

This review of randomized controlled trials for alopecia areata treatments found that none were significantly better than placebo in promoting long-term hair growth, with most trials being small and poorly reported.

The document concludes that a unique target-like hair regrowth pattern in alopecia areata may be more common than thought and should be properly identified.

This updated guideline from the British Association of Dermatologists discusses current recommendations for managing alopecia areata but reports no new clinical research findings.

This review evaluates the efficacy and safety of topical sensitizers in treating alopecia areata but reports no new clinical findings.

This article reviews recent updates on alopecia areata, focusing on its causes, clinical presentation, and treatment options, and provides treatment plans by patient age and disease extent, but reports no new clinical results.

This review discusses evidence for alopecia areata treatments, highlighting their ability to stimulate hair growth but noting limited data on long-term efficacy and impact on quality of life.